title: [Targeted therapy for metastatic bladder cancer].
abstract: The current therapy concept for metastatic bladder cancer is chemotherapy with gemcitabine and cisplatin as the first line protocol. Within the last 20 years no real progress could be achieved; the median survival is 14 months, though many different protocols have been tested. Expression analyses of growth factor receptors in human tumor tissue showed that expression of certain receptors is correlated with a severe clinical course.For many of these growth factor receptors pharmacological inhibitors are available in order to perform targeted therapy. The following review gives a survey of current studies on targeted therapy of metastatic bladder carcinoma.
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum, Hufelandstrasse 55, 45122 Essen, Deutschland. frankvomDorp@web.de
authors.forename: F
authors.initials: F
authors.lastname: Vom Dorp
authors.forename: C
authors.initials: C
authors.lastname: Börgermann
authors.forename: A
authors.initials: A
authors.lastname: Rose
authors.forename: M
authors.initials: M
authors.lastname: Becker
authors.forename: H
authors.initials: H
authors.lastname: Rübben
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage; D000068258:Bevacizumab; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D016503:Drug Delivery Systems; D000077156:Gefitinib; D006801:Humans; D000077341:Lapatinib; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors*; D000077157:Sorafenib; D015996:Survival Rate; D000068878:Trastuzumab; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D000068258:Bevacizumab; D000077156:Gefitinib; D000077341:Lapatinib; D009536:Niacinamide; D010671:Phenylurea Compounds; D011725:Pyridines; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D017978:Receptors, Growth Factor; D000077157:Sorafenib; D000068878:Trastuzumab